Covered recipient · General Payments record
WILLIAM C NABOURS
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,046.78
128 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,035.07 | 127 |
| Education | $11.71 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $405.15 | 25 |
| Novo Nordisk Inc | $222.87 | 15 |
| Lilly USA, LLC | $193.26 | 14 |
| Astellas Pharma US Inc | $124.06 | 7 |
| AstraZeneca Pharmaceuticals LP | $123.93 | 6 |
| Sunovion Pharmaceuticals Inc. | $123.42 | 10 |
| Amarin Pharma Inc. | $119.62 | 6 |
| Amgen Inc. | $100.15 | 7 |
| Kowa Pharmaceuticals America, Inc. | $98.94 | 5 |
| Merck Sharp & Dohme LLC | $98.93 | 6 |
| PFIZER INC. | $81.69 | 5 |
| Novartis Pharmaceuticals Corporation | $77.25 | 5 |
| GlaxoSmithKline, LLC. | $65.72 | 4 |
| Esperion Therapeutics, Inc. | $46.96 | 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.53 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34.82 | 2 |
| Janssen Pharmaceuticals, Inc | $31.59 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.59 | 2 |
| Daiichi Sankyo Inc. | $13.82 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.48 | 1 |
Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM C NABOURS
NPI 1659371193 · CMS profile ID 347673
Allopathic & Osteopathic Physicians / Family Medicine
LAKE CHARLES, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659371193?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659371193?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659371193?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- WILLIAM C NABOURS, NPI 1659371193, CMS profile ID 347673, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1659371193?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
128 matching records · $2,046.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 128.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $8.73 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226577 | CMS |
| Kowa Pharmaceuticals America, Inc. | $16.58 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 900460981 | CMS |
| PFIZER INC. | $20.75 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949196207 | CMS |
| Sunovion Pharmaceuticals Inc. | $3.88 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 921169489 | CMS |
| Novartis Pharmaceuticals Corporation | $15.74 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894008837 | CMS |
| Sunovion Pharmaceuticals Inc. | $4.23 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 921166785 | CMS |
| Novo Nordisk Inc | $15.16 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899051645 | CMS |
| Amgen Inc. | $12.76 | 07/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939877469 | CMS |
| ABBVIE INC. | $19.26 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226575 | CMS |
| Lilly USA, LLC | $13.10 | 07/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918362111 | CMS |
| Astellas Pharma US Inc | $17.66 | 07/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940226249 | CMS |
| Novo Nordisk Inc | $15.33 | 07/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898773877 | CMS |
| Sunovion Pharmaceuticals Inc. | $14.27 | 07/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 921061821 | CMS |
| ABBVIE INC. | $23.73 | 06/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226573 | CMS |
| Merck Sharp & Dohme LLC | $19.36 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944295299 | CMS |
| Novartis Pharmaceuticals Corporation | $16.06 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894008833 | CMS |
| Novo Nordisk Inc | $14.63 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899052025 | CMS |
| Kowa Pharmaceuticals America, Inc. | $19.88 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 900416335 | CMS |
| Lilly USA, LLC | $9.06 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918374787 | CMS |
| ABBVIE INC. | $12.86 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226571 | CMS |
| PFIZER INC. | $14.54 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949163737 | CMS |
| Sunovion Pharmaceuticals Inc. | $16.18 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 921036669 | CMS |
| Amarin Pharma Inc. | $23.44 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 913932907 | CMS |
| Astellas Pharma US Inc | $16.56 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940204223 | CMS |
| ABBVIE INC. | $23.27 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226569 | CMS |
| Lilly USA, LLC | $11.71 | 06/02/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918331529 | CMS |
| Lilly USA, LLC | $16.62 | 06/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918331533 | CMS |
| Merck Sharp & Dohme LLC | $17.53 | 05/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944165529 | CMS |
| Novo Nordisk Inc | $12.91 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899452875 | CMS |
| ABBVIE INC. | $15.07 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226567 | CMS |
| Sunovion Pharmaceuticals Inc. | $15.13 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 921050423 | CMS |
| ABBVIE INC. | $17.99 | 05/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226565 | CMS |
| ABBVIE INC. | $18.61 | 05/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226563 | CMS |
| Astellas Pharma US Inc | $17.25 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940183821 | CMS |
| Novo Nordisk Inc | $21.89 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899052049 | CMS |
| Lilly USA, LLC | $13.79 | 05/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918338887 | CMS |
| PFIZER INC. | $20.07 | 05/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949131419 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.04 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915747150 | CMS |
| Amarin Pharma Inc. | $16.76 | 05/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 913932909 | CMS |
| ABBVIE INC. | $4.67 | 04/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226561 | CMS |
| Novartis Pharmaceuticals Corporation | $13.08 | 04/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894008829 | CMS |
| Esperion Therapeutics, Inc. | $17.57 | 04/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947272953 | CMS |
| Amgen Inc. | $16.01 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939877467 | CMS |
| ABBVIE INC. | $3.88 | 04/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891226559 | CMS |
| Kowa Pharmaceuticals America, Inc. | $26.51 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 900373021 | CMS |
| Lilly USA, LLC | $11.62 | 04/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918374789 | CMS |
| Amarin Pharma Inc. | $20.81 | 04/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 913965119 | CMS |
| Astellas Pharma US Inc | $17.53 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940158307 | CMS |
| Amgen Inc. | $11.16 | 03/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939286405 | CMS |
| GlaxoSmithKline, LLC. | $14.27 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944294553 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,118,331.43 | 11 |
| PY2024 | Recipient | $173,371.00 | 3 |
| PY2024 | Principal investigator | $857,135.62 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
11 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,400.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185545525 |
| Principal investigator 1 | Eli Lilly and Company | $158,454.57 | 08/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) | No dispute reported | 06/30/2026 | 1187883342 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,452.80 | 08/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185545523 |
| Principal investigator 1 | Eli Lilly and Company | $2.13 | 06/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS OF SWLA LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187879501 |
| Principal investigator 1 | Eli Lilly and Company | $824,804.85 | 04/21/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY | No dispute reported | 06/30/2026 | 1187877351 |
| Principal investigator 1 | Eli Lilly and Company | $621.22 | 01/31/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187876497 |
| Principal investigator 1 | Eli Lilly and Company | $10,157.85 | 01/27/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187875459 |
| Principal investigator 1 | Eli Lilly and Company | $3,065.01 | 01/26/2025 | Non-covered Recipient Entity VANCOUVER CLINIC INC PS | A PHASE 3B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO- CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY (TRIUMPH-6) | No dispute reported | 06/30/2026 | 1187892024 |
| Principal investigator 1 | Eli Lilly and Company | $506,057.00 | 01/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187875455 |
| Principal investigator 1 | Eli Lilly and Company | $522,872.00 | 01/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187876737 |
| Principal investigator 1 | Eli Lilly and Company | $47,444.00 | 01/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187878279 |